Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jul;72(1):178–182. doi: 10.1038/bjc.1995.298

Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor.

S Leyvraz 1, N Ketterer 1, L Perey 1, J Bauer 1, P Vuichard 1, J P Grob 1, P Schneider 1, V von Fliedner 1, F Lejeune 1, F Bachmann 1
PMCID: PMC2034125  PMID: 7541235

Abstract

Dose intensity may be an important determinant of the outcome in cancer chemotherapy, but is often limited by cumulative haematological toxicity. The availability of haematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and of peripheral blood progenitor cell (PBPC) transplantation has allowed the development of a new treatment strategy in which several courses of high-dose combination chemotherapy are administered for the treatment of solid tumours. PBPCs were mobilised before chemotherapy using 12 or 30 micrograms kg-1 day-1 G-CSF (Filgrastim) for 10 days, and were collected by 2-5 leucaphereses. The yields of mononuclear cells, colony-forming units and CD34-positive cells were similar at the two dose levels of Filgrastim, and the numbers of PBPCs were sufficient for rescue following multiple cycles of chemotherapy. High-dose chemotherapy (cyclophosphamide 2.5 g m-2 for 2 days, etoposide 300 mg m-2 for 3 days and cisplatin 50 mg m-2 for 3 days) was administered sequentially for a median of three cycles (range 1-4) to ten patients. Following the 30 evaluable cycles, the median duration of leucopenia < or = 0.5 x 10(9) l-1 and < or = 1.0 x 10(9) l-1 was 7 and 8 days respectively. The median time of thrombopenia < or = 20 x 10(9) l-1 was 6 days. There was no cumulative haematological toxicity. The duration of leucopenia, but not of thrombopenia, was inversely related to the number of reinfused CFU-GM (granulocyte-macrophage colony-forming units). In the majority of patients, neurotoxicity and ototoxicity became dose limiting after three cycles of therapy. However, the average dose intensity delivered was about three times higher than in a standard regimen. The complete response rate in patients with small-cell lung cancers was 66% (95% CI 30-92%) and the median progression-free survival and overall survival were 13 months and 17 months respectively. These results are encouraging and should be compared, in a randomised fashion, with standard dose chemotherapy.

Full text

PDF
178

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardizzoni A., Venturini M., Crinò L., Sertoli M. R., Bruzzi P., Pennucci M. C., Mariani G. L., Garrone O., Bracarda S., Rosso R. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer. Eur J Cancer. 1993;29A(5):687–692. doi: 10.1016/s0959-8049(05)80347-8. [DOI] [PubMed] [Google Scholar]
  2. Arriagada R., Le Chevalier T., Pignon J. P., Rivière A., Monnet I., Chomy P., Tuchais C., Tarayre M., Ruffié P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993 Dec 16;329(25):1848–1852. doi: 10.1056/NEJM199312163292504. [DOI] [PubMed] [Google Scholar]
  3. Cortés Funes H., Dominguez P., Torrubia A. P., Lanzos E., Mendez M., Mendiola C. Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapy. Cancer Chemother Pharmacol. 1982;7(2-3):181–186. doi: 10.1007/BF00254545. [DOI] [PubMed] [Google Scholar]
  4. Crown J., Wassherheit C., Hakes T., Fennelly D., Reich L., Moore M., Schneider J., Curtin J., Rubin S. C., Reichman B. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J Natl Cancer Inst. 1992 Dec 16;84(24):1935–1936. doi: 10.1093/jnci/84.24.1935. [DOI] [PubMed] [Google Scholar]
  5. Elias A. D., Ayash L., Frei E., 3rd, Skarin A. T., Hunt M., Wheeler C., Schwartz G., Mazanet R., Tepler I., Eder J. P. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst. 1993 Apr 7;85(7):559–566. doi: 10.1093/jnci/85.7.559. [DOI] [PubMed] [Google Scholar]
  6. Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988:121–141. [PubMed] [Google Scholar]
  7. Johnson D. H., DeLeo M. J., Hande K. R., Wolff S. N., Hainsworth J. D., Greco F. A. High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer. J Clin Oncol. 1987 May;5(5):703–709. doi: 10.1200/JCO.1987.5.5.703. [DOI] [PubMed] [Google Scholar]
  8. Kritz A., Crown J. P., Motzer R. J., Reich L. M., Heller G., Moore M. P., Hamilton N., Yao T. J., Heelan R. T., Schneider J. G. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. Cancer. 1993 Apr 15;71(8):2515–2521. doi: 10.1002/1097-0142(19930415)71:8<2515::aid-cncr2820710814>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  9. Leyvraz S., Ketterer N., Vuichard P., von Fliedner V., Lejeune F., Schneider P., Grob J. P., Bachmann F. Sequential high-dose combination chemotherapy with granulocyte colony-stimulating factor and peripheral blood progenitor cells in patients with solid tumors: intensification limited by nonhematologic toxic effects. J Natl Cancer Inst. 1993 Dec 1;85(23):1962–1964. doi: 10.1093/jnci/85.23.1962. [DOI] [PubMed] [Google Scholar]
  10. Linch D. C., Scarffe H., Proctor S., Chopra R., Taylor P. R., Morgenstern G., Cunningham D., Burnett A. K., Cawley J. C., Franklin I. M. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant. 1993 Apr;11(4):307–311. [PubMed] [Google Scholar]
  11. Longo D. L., Duffey P. L., DeVita V. T., Jr, Wesley M. N., Hubbard S. M., Young R. C. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol. 1991 Nov;9(11):2042–2051. doi: 10.1200/JCO.1991.9.11.2042. [DOI] [PubMed] [Google Scholar]
  12. Miles D. W., Fogarty O., Ash C. M., Rudd R. M., Trask C. W., Spiro S. G., Gregory W. M., Ledermann J. A., Souhami R. L., Harper P. G. Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol. 1994 Jan;12(1):77–82. doi: 10.1200/JCO.1994.12.1.77. [DOI] [PubMed] [Google Scholar]
  13. Murray N. The importance of dose and dose intensity in lung cancer chemotherapy. Semin Oncol. 1987 Dec;14(4 Suppl 4):20–28. [PubMed] [Google Scholar]
  14. Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649–655. [PubMed] [Google Scholar]
  15. Pike B. L., Robinson W. A. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970 Aug;76(1):77–84. doi: 10.1002/jcp.1040760111. [DOI] [PubMed] [Google Scholar]
  16. Shea T. C., Mason J. R., Breslin M., Bissent E., Mullen M., Taetle R. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy. J Clin Oncol. 1994 May;12(5):1012–1020. doi: 10.1200/JCO.1994.12.5.1012. [DOI] [PubMed] [Google Scholar]
  17. Shimazaki C., Oku N., Uchiyama H., Yamagata N., Tatsumi T., Hirata T., Ashihara E., Okawa K., Goto H., Inaba T. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 1994 Mar;13(3):271–275. [PubMed] [Google Scholar]
  18. Souhami R. L., Finn G., Gregory W. M., Birkhead B. G., Buckman R., Edwards D., Goldstone A. H., Harper P. G., Spiro S. G., Tobias J. S. High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol. 1985 Jul;3(7):958–963. doi: 10.1200/JCO.1985.3.7.958. [DOI] [PubMed] [Google Scholar]
  19. Teicher B. A., Holden S. A., Eder J. P., Brann T. W., Jones S. M., Frei E., 3rd Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res. 1989 Nov 1;49(21):5994–5998. [PubMed] [Google Scholar]
  20. Teshima T., Harada M., Takamatsu Y., Makino K., Inaba S., Akashi K., Kondo S., Tanaka T., Ishii E., Niho Y. Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells. Br J Haematol. 1993 Aug;84(4):570–573. doi: 10.1111/j.1365-2141.1993.tb03129.x. [DOI] [PubMed] [Google Scholar]
  21. van der Wall E., Richel D. J., Holtkamp M. J., Slaper-Cortenbach I. C., van der Schoot C. E., Dalesio O., Nooijen W. J., Schornagel J. H., Rodenhuis S. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol. 1994 Nov;5(9):795–802. doi: 10.1093/oxfordjournals.annonc.a059007. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES